A novel prognostic biomarker for muscle invasive bladder urothelial carcinoma based on 11 DNA methylation signature

References

• Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. 2017. Bladder cancer. Nat rev Dis Primers. 3:17022. doi:10.1038/nrdp.2017.22.
   PubMed Web of Science ®Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. 2017. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol. 71:96–108. doi:10.1016/j.eururo.2016.06.010.
   PubMed Web of Science ®Google Scholar
• Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, et al. 2013. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 63:234–241. doi:10.1016/j.eururo.2012.07.033.
   PubMed Web of Science ®Google Scholar
• Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006;176:486–492. discussion 491-2. doi:10.1016/j.juro.2006.03.038.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A, Group EGW. 2014. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25(Suppl 3):iii40–8. doi:10.1093/annonc/mdu223.
   PubMed Web of Science ®Google Scholar
• Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al. 2000. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 18:3068–3077. doi:10.1200/JCO.2000.18.17.3068.
   PubMed Web of Science ®Google Scholar
• Henrique R, Nunes SP, Jeronimo C. 2018. MSH2 expression and resistance to cisplatin in muscle-invasive bladder cancer: A mix of progress and challenges. Eur Urol. doi:10.1016/j.eururo.2018.11.014
   PubMed Web of Science ®Google Scholar
• Berdik C. 2017. Unlocking bladder cancer. Nature. 551:S34–S35. doi:10.1038/551S34a.
   PubMed Web of Science ®Google Scholar
• Moore LD, Le T, Fan G. 2013. DNA methylation and its basic function. Neuropsychopharmacology. 38:23–38. doi:10.1038/npp.2012.112.
   PubMed Web of Science ®Google Scholar
• Arantes LM, de Carvalho AC, Melendez ME, Carvalho AL, Goloni-Bertollo EM. 2014. Methylation as a biomarker for head and neck cancer. Oral Oncol. 50:587–592. doi:10.1016/j.oraloncology.2014.02.015.
   PubMed Web of Science ®Google Scholar
• Esteller M. 2008. Epigenetics in cancer. N Engl J Med. 358:1148–1159. doi:10.1056/NEJMra072067.
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. 2003. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349:2042–2054. doi:10.1056/NEJMra023075.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, et al. 2008. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 456:66–72. doi:10.1038/nature07485.
   PubMed Web of Science ®Google Scholar
• Shivakumar M, Lee Y, Bang L, Garg T, Sohn KA, Kim D. 2017. Identification of epigenetic interactions between miRNA and DNA methylation associated with gene expression as potential prognostic markers in bladder cancer. BMC Med Genomics. 10:30. doi:10.1186/s12920-017-0269-y.
   PubMed Web of Science ®Google Scholar
• Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, Fussel S, Novotny V, Toma M, Gajda M, et al. 2019. A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. J Cancer Res Clin Oncol. doi:10.1007/s00432-018-02829-4.
   PubMed Web of Science ®Google Scholar
• Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, et al. 2009. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 462:315–322. doi:10.1038/nature08514.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, He QY. 2015. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics. 31:2382–2383. doi:10.1093/bioinformatics/btv145.
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S. 2013. A beta-mixture quantile normalization method for correcting probe design bias in illumina infinium 450 k DNA methylation data. Bioinformatics. 29:189–196. doi:10.1093/bioinformatics/bts680.
   PubMed Web of Science ®Google Scholar
• Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, Wojdacz TK, Beck S. 2014. ChAMP: 450k chip analysis methylation pipeline. Bioinformatics. 30:428–430. doi:10.1093/bioinformatics/btt684.
   PubMed Web of Science ®Google Scholar
• Johnson WE, Li C, Rabinovic A. 2007. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 8:118–127. doi:10.1093/biostatistics/kxj037.
   PubMed Web of Science ®Google Scholar
• Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM. 2010. Comparison of beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinform. 11:587. doi:10.1186/1471-2105-11-587.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e47. doi:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, Irizarry RA. 2012. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol. 41:200–209. doi:10.1093/ije/dyr238.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang K. 2015. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 10:1556–1566. doi:10.1038/nprot.2015.105.
   PubMed Web of Science ®Google Scholar
• Yu GC, Wang LG, Han YY, He QY. 2012. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 16:284–287. doi:10.1089/omi.2011.0118.
   PubMed Web of Science ®Google Scholar
• Zhang HH, Lu WB. 2007. Adaptive lasso for Cox’s proportional hazards model. Biometrika. 94:691–703. doi:10.1093/biomet/asm037.
   Web of Science ®Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. 2000. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 56:337–344. doi:10.1111/j.0006-341X.2000.00337.x.
   PubMed Web of Science ®Google Scholar
• Feng N, Wang Y, Zheng M, Yu X, Lin H, Ma RN, Shi O, Zheng X, Gao M, Yu H, et al. 2017. Genome-wide analysis of DNA methylation and their associations with long noncoding RNA/mRNA expression in non-small-cell lung cancer. Epigenomics. doi:10.2217/epi-2016-0120.
   Web of Science ®Google Scholar
• Chan KC, Jiang P, Chan CW, Sun K, Wong J, Hui EP, Chan SL, Chan WC, Hui DS, Ng SS, et al. 2013. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A. 110:18761–18768. doi:10.1073/pnas.1313995110.
   PubMed Web of Science ®Google Scholar
• Ambrosi C, Manzo M, Baubec T. 2017. Dynamics and context-dependent roles of DNA methylation. J Mol Biol. 429:1459–1475. doi:10.1016/j.jmb.2017.02.008.
   PubMed Web of Science ®Google Scholar
• Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, et al. 2018. METTL13 methylation of eEF1A increases translational output to promote tumorigenesis. Cell. doi:10.1016/j.cell.2018.11.038.
   Web of Science ®Google Scholar
• Naeve GS, Ramakrishnan M, Kramer R, Hevroni D, Citri Y, Theill LE. Neuritin: a gene induced by neural activity and neurotrophins that promotes neuritogenesis. Proc Natl Acad Sci U S A. 1997;94:2648–2653. doi:10.1073/pnas.94.6.2648.
   PubMed Web of Science ®Google Scholar
• Le Jan S, Le Meur N, Cazes A, Philippe J, Le Cunff M, Leger J, Corvol P and Germain S. 2006. Characterization of the expression of the hypoxia-induced genes neuritin, TXNIP and IGFBP3 in cancer. FEBS Lett. 580:3395–3400. doi:10.1016/j.febslet.2006.05.011.
   PubMed Web of Science ®Google Scholar
• Raso A, Mascelli S, Biassoni R, Nozza P, Kool M, Pistorio A, Ugolotti E, Milanaccio C, Pignatelli S, Ferraro M, et al. 2011. High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma. Neuro-oncology. 13:500–508. doi:10.1093/neuonc/nor022.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen H, Lv S, Yang H. 2016. High CD133 expression is associated with worse prognosis in patients with glioblastoma. Mol Neurobiol. 53:2354–2360. doi:10.1007/s12035-015-9187-1.
   PubMed Web of Science ®Google Scholar
• Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, Ogawa T, Takebayashi S, Grenman RA, Herman JG, et al. 2008. Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res. 14:7604–7613. doi:10.1158/1078-0432.CCR-07-4673.
   PubMed Web of Science ®Google Scholar
• Stevenson L, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart G, Lenz HJ, Van Schaeybroeck S, Longley DB, Johnston PG. 2012. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin Cancer Res. 18:5412–5426. doi:10.1158/1078-0432.CCR-12-1780.
   PubMed Web of Science ®Google Scholar
• Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, et al. 2014. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 13:397–406. doi:10.1074/mcp.M113.035600.
   PubMed Web of Science ®Google Scholar
• Moissoglu K, McRoberts KS, Meier JA, Theodorescu D and Schwartz M A. 2009. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 69:2838–2844. doi:10.1158/0008-5472.CAN-08-1397.
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr. 2004. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 10:3800–3806. doi:10.1158/1078-0432.CCR-03-0653.
   PubMed Web of Science ®Google Scholar
• Said N, Sanchez-Carbayo M, Smith SC, Theodorescu D. 2012. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest. 122:1503–1518. doi:10.1172/JCI61392.
   PubMed Web of Science ®Google Scholar
• Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002;62:6418–6423.
   PubMed Web of Science ®Google Scholar
• Peykov S, Berkel S, Schoen M, Weiss K, Degenhardt F, Strohmaier J, Weiss B, Proepper C, Schratt G, Nothen MM, et al. 2015. Identification and functional characterization of rare SHANK2 variants in schizophrenia. Mol Psychiatry. 20:1489–1498. doi:10.1038/mp.2014.172.
   PubMed Web of Science ®Google Scholar
• Barros-Filho MC, Reis-Rosa LA, Hatakeyama M, Marchi FA, Chulam T, Scapulatempo-Neto C, Nicolau UR, Carvalho AL, Pinto CAL, Drigo SA, et al. 2018. Oncogenic drivers in 11q13 associated with prognosis and response to therapy in advanced oropharyngeal carcinomas. Oral Oncol. 83:81–90. doi:10.1016/j.oraloncology.2018.06.010.
   PubMed Web of Science ®Google Scholar
• Freier K, Sticht C, Hofele C, Flechtenmacher C, Stange D, Puccio L, Toedt G, Radlwimmer B, Lichter P, Joos S. 2006. Recurrent coamplification of cytoskeleton-associated genes EMS1 and SHANK2 with CCND1 in oral squamous cell carcinoma. Genes Chromosomes Cancer. 45:118–125. doi:10.1002/gcc.20270.
   PubMed Web of Science ®Google Scholar
• Calvo F, Sanz-Moreno V, Agudo-Ibanez L, Wallberg F, Sahai E, Marshall CJ, Crespo P. 2011. RasGRF suppresses Cdc42-mediated tumour cell movement, cytoskeletal dynamics and transformation. Nat Cell Biol. 13:819–826. doi:10.1038/ncb2271.
   PubMed Web of Science ®Google Scholar
• Kato T, Shimono Y, Hasegawa M, Jijiwa M, Enomoto A, Asai N, Murakumo Y and Takahashi M. 2009. Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress. Cancer Res. 69:3597–3604. doi:10.1158/0008-5472.CAN-08-4368.
   PubMed Web of Science ®Google Scholar
• Chung AS, Guan YJ, Yuan ZL, Albina JE, Chin YE. 2005. Ankyrin repeat and SOCS box 3 (ASB3) mediates ubiquitination and degradation of tumor necrosis factor receptor II. Mol Cell Biol. 25:4716–4726. doi:10.1128/MCB.25.11.4716-4726.2005.
   PubMed Web of Science ®Google Scholar
• Peterfi Z, Geiszt M. 2014. Peroxidasins: novel players in tissue genesis. Trends Biochem Sci. 39:305–307. doi:10.1016/j.tibs.2014.05.005.
   PubMed Web of Science ®Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al. 2017. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 171:540–556 e25. doi:10.1016/j.cell.2017.09.007.
   PubMed Web of Science ®Google Scholar
• Xie G, Dong C, Kong Y, Zhong JF, Li M, Wang K. 2019. Group lasso regularized deep learning for cancer prognosis from multi-omics and clinical features. Genes (Basel). 10. doi:10.3390/genes10030240.
   Web of Science ®Google Scholar
• Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA. 2016. Gender and bladder cancer: A collaborative review of etiology, biology, and outcomes. Eur Urol. 69:300–310. doi:10.1016/j.eururo.2015.08.037.
   PubMed Web of Science ®Google Scholar